“…https://doi.org/10.51126/revsalus.v4iSup.399 https://doi.org/10.51126/revsalus.v4iSup.400 R e v i s t a C i e n t í f i c a I n t e r n a c i o n a l R e v S A L U S 1 6 Differential cellular effects of sunitinib and pazopanib targeted drugs for metastatic renal cell carcinoma -an in vitro approach Maria João Valente 3 , Vera Miranda-Gonçalves 4 , Carmen Jerónimo 4,5 , Rui Henrique4,5,6 , Maria de Lourdes Bastos 1,2 , Paula Guedes de Pinho 1,2 , Márcia Carvalho 1,2,7,8 , Joana Pinto1,2 Resumo Introduction: Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) that have been widely used as first-line treatments for advanced Renal Cell Carcinoma (RCC).…”